Northland Securities set a $20.00 price objective on Flexion Therapeutics (NASDAQ:FLXN) in a research note issued to investors on Tuesday, TipRanks reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
Other equities analysts also recently issued reports about the stock. ValuEngine upgraded shares of Flexion Therapeutics from a sell rating to a hold rating in a report on Thursday, May 23rd. Zacks Investment Research raised shares of Flexion Therapeutics from a hold rating to a buy rating and set a $12.00 target price for the company in a research report on Saturday, August 10th. Finally, BidaskClub raised shares of Flexion Therapeutics from a hold rating to a buy rating in a research report on Wednesday, September 4th. Ten analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus price target of $23.57.
Shares of NASDAQ:FLXN traded down $0.21 on Tuesday, hitting $13.92. The company had a trading volume of 1,102 shares, compared to its average volume of 520,452. Flexion Therapeutics has a 1-year low of $8.76 and a 1-year high of $21.77. The stock has a market cap of $543.02 million, a price-to-earnings ratio of -3.11 and a beta of 1.23. The stock has a 50 day moving average price of $11.29 and a 200 day moving average price of $11.69. The company has a current ratio of 7.80, a quick ratio of 7.33 and a debt-to-equity ratio of 3.95.
In other Flexion Therapeutics news, insider Michael D. Clayman bought 2,317 shares of Flexion Therapeutics stock in a transaction dated Thursday, August 8th. The stock was bought at an average price of $10.85 per share, with a total value of $25,139.45. Following the completion of the transaction, the insider now owns 72,249 shares in the company, valued at approximately $783,901.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 16.01% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of FLXN. Quantamental Technologies LLC lifted its position in Flexion Therapeutics by 310.1% during the second quarter. Quantamental Technologies LLC now owns 3,449 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 2,608 shares during the period. Aperio Group LLC bought a new stake in Flexion Therapeutics during the second quarter worth about $46,000. Cutler Group LP lifted its position in Flexion Therapeutics by 2,650.0% during the second quarter. Cutler Group LP now owns 5,500 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 5,300 shares during the period. BNP Paribas Arbitrage SA lifted its position in Flexion Therapeutics by 53,692.3% during the first quarter. BNP Paribas Arbitrage SA now owns 6,993 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 6,980 shares during the period. Finally, Paradigm Capital Management Inc. NY bought a new stake in Flexion Therapeutics during the second quarter worth about $123,000. 84.87% of the stock is owned by institutional investors and hedge funds.
About Flexion Therapeutics
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Recommended Story: Percentage Gainers
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.